Metformin decreases circulating acylation-stimulating protein levels in polycystic ovary syndrome
Authors:
- Cagatay OktenliCOCagatay Oktenli
- Taner OzgurtasTOTaner Ozgurtas
- Murat DedeMDMurat Dede
- Yavuz S. SanisogluYSYavuz S. Sanisoglu
- Mufit C. YenenMYMufit C. Yenen
- Zeki YesilovaZYZeki Yesilova
- Levent KenarLKLevent Kenar
- Yasemin G. KurtYKYasemin G. Kurt
- Iskender BaserIBIskender Baser
- Jessica SmithJSJessica Smith
- Katherine CianfloneKCKatherine Cianflone
- 1 January 2007
- journal article
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 23 (12) , 710-715
Abstract
There are no studies that examine the circulating acylation-stimulating protein (ASP) levels in patients with polycystic ovary syndrome (PCOS). The present study was designed to determine the ASP levels in PCOS and to evaluate the effect of metformin on plasma fasting ASP concentrations. Twenty women with PCOS and 20 healthy controls matched for age and body mass index (BMI) were included in the study. We determined ASP and other biochemical parameters before and after treatment. Baseline levels of plasma ASP, complement 3 (C3), waist-to-hip ratio (WHR), homeostasis model assessment-insulin resistance index (HOMA-IR), fasting insulin, triglycerides (TG) and very-low-density lipoprotein cholesterol (VLDL-C) were significantly higher in patients than in controls. After 3 months of metformin treatment, BMI, WHR, ASP, C3, fasting glucose, fasting insulin, HOMA-IR, total cholesterol, TG, VLDL-C and free testosterone decreased significantly, whereas apolipoprotein A-I and high-density lipoprotein cholesterol increased significantly. The major novel information of the present study is that ASP and C3 values are markedly increased in non-obese patients with PCOS, with a decrease evidenced with metformin treatment.Keywords
This publication has 22 references indexed in Scilit:
- Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistanceHuman Reproduction, 2005
- Evidence for altered adipocyte function in polycystic ovary syndromeEuropean Journal of Endocrinology, 2005
- Fasting acylation-stimulating protein is predictive of postprandial triglyceride clearanceJournal of Lipid Research, 2004
- Acylation stimulating protein stimulates insulin secretionInternational Journal of Obesity, 2003
- The importance of insulin resistance in polycystic ovary syndromeFertility and Sterility, 2003
- The Chemoattractant Receptor-like Protein C5L2 Binds the C3a des-Arg77/Acylation-stimulating ProteinJournal of Biological Chemistry, 2003
- Critical review of acylation-stimulating protein physiology in humans and rodentsBiochimica et Biophysica Acta (BBA) - Biomembranes, 2003
- Acylation-stimulating Protein (ASP) Deficiency Induces Obesity Resistance and Increased Energy Expenditure in ob/obMiceJournal of Biological Chemistry, 2002
- Increased Fasting Plasma Acylation-Stimulating Protein Concentrations in Nephrotic SyndromeThe Journal of Clinical Endocrinology & Metabolism, 2002
- Non-esterified fatty acid metabolism and postprandial lipaemiaAtherosclerosis, 1998